Mammoth Biosciences
Janice Chen is the co-founder & CTO of Mammoth Biosciences, where Janice is utilizing novel CRISPR systems to advance the platform's ability to decode and manipulate genetic information. Prior to this, Janice conducted graduate research at University of California, Berkeley focusing on DNA-cutting CRISPR proteins and at Harvard Medical School on renewable energy solutions. Janice also has experience as an undergraduate researcher at Johns Hopkins Bloomberg School of Public Health and as a research intern at K-RITH, where Janice delved into the role of metal ions in biology and molecular signals triggering tuberculosis. Janice holds a Ph.D. in Molecular and Cell Biology from University of California, Berkeley and a B.S. in Molecular and Cellular Biology from The Johns Hopkins University.
This person is not in any offices
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.